STOCK TITAN

InspireMD Inc - NSPR STOCK NEWS

Welcome to our dedicated news page for InspireMD (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on InspireMD.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect InspireMD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of InspireMD's position in the market.

Rhea-AI Summary
InspireMD, Inc. (NSPR) appoints principal investigators for upcoming C-GUARDIANS II clinical trial of SwitchGuard™ Neuroprotection System, aiming to support Carotid Artery Stenting and Transcarotid Artery Revascularization procedures. The trial, led by renowned experts in vascular surgery, aims to advance the clearance of SwitchGuard™ NPS for improved patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
management clinical trial
-
Rhea-AI Summary
InspireMD, Inc. (NSPR) has received CE Mark recertification under the European Union's new Medical Device Regulation for its CGuard™ Embolic Prevention Carotid Stent System. The company is also making progress on the Premarket Approval Application for the C-GUARDIANS U.S. IDE trial and looks forward to primary endpoint results in mid-2024. InspireMD continues to work towards multiple value-creating milestones, including potential U.S. approval of the CGuard Prime EPS stent system in the first half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
none
-
Rhea-AI Summary
InspireMD (Nasdaq: NSPR) appoints Pete Ligotti as Executive Vice President and General Manager of North America, bringing over 30 years of experience in medical technology. The company also grants Mr. Ligotti 138,460 shares of restricted stock and stock options to purchase 46,150 shares of common stock under NASDAQ listing rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
management
Rhea-AI Summary
InspireMD (Nasdaq: NSPR) announced the issuance of U.S. Patent No. 11,844,893, covering the SwitchGuard™ Neuroprotection System (NPS) for carotid artery disease treatment. The company aims to provide a complete solution set for carotid artery disease and stroke prevention, with a focus on expanding their product portfolio and adding intellectual property to support innovations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.5%
Tags
none
-
Rhea-AI Summary
InspireMD, developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, has entered into a strategic agreement with the Jacobs Institute at the State University of New York at Buffalo and Dr. Adnan Siddiqui to execute an Early Feasibility Study (EFS) evaluating the CGuard EPS carotid stent to treat severe carotid stenosis or occlusion, in conjunction with thrombectomy, in patients presenting with acute ischemic stroke and tandem lesions. The EFS is expected to enroll 15 patients across three U.S. trial sites and explore the safety and feasibility of using the CGuard EPS carotid stent, with its unique MicroNet™ mesh covering, to treat acute ischemic stroke patients with tandem lesions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.41%
Tags
none
-
Rhea-AI Summary
InspireMD, Inc. announced positive 30-day results from the C-GUARDIANS U.S. clinical trial, with a major adverse events rate of 0.95%. They also announced support for CMS' final decision to expand coverage of CAS to include more patients. Q3 2023 revenue was $1.56 million, up 9% from Q3 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.19%
Tags
earnings
Rhea-AI Summary
InspireMD, Inc. announced that CEO Marvin Slosman will participate in three upcoming investor conferences in November. The conferences include Wolfe Research Healthcare Conference on November 15, Canaccord Genuity MedTech, Diagnostics, Digital Health & Services Forum on November 16, and Piper 35th Annual Healthcare Conference on November 29. The presentations will be available as a live webcast on the company's website with replays available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.41%
Tags
conferences
-
Rhea-AI Summary
InspireMD presents 30-day results from the C-GUARDIANS trial at the VIVA meeting. The trial evaluated the safety and efficacy of the CGuard Carotid Stent System in treating carotid artery stenosis. The primary endpoint showed a low major adverse event rate of 0.95% through 30 days post-procedure. InspireMD anticipates reporting primary endpoint results in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.21%
Tags
clinical trial
-
Rhea-AI Summary
InspireMD, Inc. (Nasdaq: NSPR) will report its third quarter 2023 financial results on November 6th, 2023. The company will host a conference call and webcast at 8:30 a.m. EST on the same day to review financial results and provide corporate updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.07%
Tags
conferences earnings
Rhea-AI Summary
InspireMD supports CMS's expansion of coverage for carotid artery stenting, potentially increasing market size
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
none
InspireMD Inc

Nasdaq:NSPR

NSPR Rankings

NSPR Stock Data

56.24M
8.97M
21.92%
47.98%
0.42%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Israel
4 Menorat Hamaor St

About NSPR

inspiremd, inc. is a company based out of 800 boylston street suite 16041, boston, massachusetts, united states.